GM-XANTHO successfully achieved the clinical trial enrollment milestone in January 2025!

Xantho Bio successfully completed the "A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GMXANTHO in Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis Patients" clinical trial enrollment (Last Subject Out, LSO) milestone in January 2025 !

All participants have completed the relevant clinical trial procedures, marking a critical step forward in our new drug development journey. We expect to complete the subsequent data analysis  in the second quarter of 2025, and will focus on continuing to drive the new drug development process forward.

Disclaimer

This article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change.